NCT03024151 is a NA clinical trial of Comthyroid in Thyroid Cancer, sponsored by Inje University.

Who is sponsoring NCT03024151?

NCT03024151 is sponsored by Inje University.

What drugs are being tested in NCT03024151?

Interventions in NCT03024151: Comthyroid, Synthroid.

What condition does NCT03024151 study?

NCT03024151 studies Thyroid Cancer, Distress, Depression, Anxiety, Fatigue.

Is NCT03024151 still recruiting?

NCT03024151 is currently completed. Last updated 20 February 2019.

Last reviewed 2019-02-20 · How we verify

NCT03024151

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of T4 Mono Replacement Versus T4/T3 Combination Replacement on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients; Prospective, Randomized, Double Blind, T4 Comparative Clinical Study

Completed NA Last updated 20 February 2019

What this trial tests

NA trial testing Comthyroid in Thyroid Cancer in 150 participants. Completed in 1 November 2017.

Timeline

1 December 2016

Primary endpoint
1 November 2017

1 November 2017

Quick facts

Lead sponsor	Inje University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	150
Start date	1 December 2016
Primary completion	1 November 2017
Estimated completion	1 November 2017
Sites	2 locations across South Korea

Drugs / interventions tested

Comthyroid — full drug profile →
Synthroid — full drug profile →

Conditions studied

Thyroid Cancer — all drugs for Thyroid Cancer →
Distress — all drugs for Distress →
Depression — all drugs for Depression →
Anxiety — all drugs for Anxiety →

Sponsor

Inje University

Who can join

Adults 20 to 70, any sex, with Thyroid Cancer or Distress. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Psychological distress (depression or anxiety) assessed with HADS
Time frame: baseline, 24 weeks
Change from baseline HADS total score at 24 weeks
Fatigue assessed with MDASI-F
Time frame: baseline, 24 weeks
Change from baseline MDASI-F score at 24 weeks

Sponsor's own description

The goal of this research is to compare the effects on psychological distress between T4 mono replacement group and T4/T3 combination replacement group after total thyroidectomy in thyroid cancer patients. 1. Subjects: * Psychologically distressed patients, such as depression, anxiety, and fatigue patient after total thyroidectomy with thyroid cancer are considered for participation. Screening of distress after total thyroidectomy is used HADS (Hospital Anxiety and Depression Scale) ≥ 8 for depression or anxiety, and MDASI-F (MD Anderson Symptom Inventory -Fatigue) ≥ 4 for fatigue. 2. Randomization: * Using the table of random sampling numbers, patients assign to T4 mono replacement group or T4/T3 combination replacement group. 3. Evaluation for distress: * Assessment will be made baseline, 4 weeks, 12 weeks and 24 weeks to investigate change of psychological distress (depression, anxiety, and fatigue). Level of distress after thyroidectomy will determine using Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI) for depression or anxiety, and Brief Fatigue Inventory (BFI) for fatigue.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Other Inje University trials

Trials by the same sponsor.

NCT07318428 — AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma · NA · enrolling by invitation
NCT05636189 — Effect of Prewarming During Induction of General Anesthesia Combined With Warmed Intravenous Fluid on Core Temperature. · NA · completed
NCT05766644 — App-based Education Program for CKD · NA · unknown
NCT05514405 — Effect of Remimazolam and Propofol on Postoperative Delirium · NA · recruiting
NCT05439057 — Effect of Remimazolam on Postoperative Nausea and Vomiting · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03024151 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inje University
Last refreshed: 20 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03024151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing